Luke Dreisbach

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

Thomas J. Lynch, Taral Patel, Luke Dreisbach et al. · Journal of Clinical Oncology · 2010 · 447 citations

Results Median Pfs-irrc, Medicine, Cancer Management +12

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Azra Raza, James A. Reeves, Eric J. Feldman et al. · Blood · 2007 · 422 citations · Full text

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

Alain P. Algazi, Megan Othus, Adil Daud et al. · Nature Medicine · 2020 · 108 citations · Full text

Tumor Biology, Randomized Phase 2, Medicine +9

B3-03: A randomized multicenter phase III study of cetuximab (Erbitux®) in combination with Taxane/Carboplatin versus Taxane/Carboplatin alone as first-line treatment for patients with advanced/metastatic Non-small cell lung cancer (NSCLC)

Thomas J. Lynch, Taral Patel, Luke Dreisbach et al. · Journal of Thoracic Oncology · 2007 · 84 citations · Full text

Medicine, Pathology, Taxane/carboplatin Versus Taxane/carboplatin +6